Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling
• AS-Ⅳ alleviated abnormal permeability and TJ expression of gut induced by sepsis. • AS-Ⅳ inhibited RhoA/NLRP3 inflammasome signaling activated by sepsis. • AS-Ⅳ attenuated gut barrier impairment by suppressing RhoA/NLRP3 inflammasome.
Gespeichert in:
| Autor*in: |
Xie, Shuhua [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: International immunopharmacology - Laupland, Kevin B. ELSEVIER, 2022, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:78 ; year:2020 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.intimp.2019.106066 |
|---|
| Katalog-ID: |
ELV048941867 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV048941867 | ||
| 003 | DE-627 | ||
| 005 | 20230624151147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200108s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2019.106066 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001992.pica |
| 035 | |a (DE-627)ELV048941867 | ||
| 035 | |a (ELSEVIER)S1567-5769(19)32274-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.75 |2 bkl | ||
| 100 | 1 | |a Xie, Shuhua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling |
| 264 | 1 | |c 2020 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • AS-Ⅳ alleviated abnormal permeability and TJ expression of gut induced by sepsis. • AS-Ⅳ inhibited RhoA/NLRP3 inflammasome signaling activated by sepsis. • AS-Ⅳ attenuated gut barrier impairment by suppressing RhoA/NLRP3 inflammasome. | ||
| 650 | 7 | |a Sepsis |2 Elsevier | |
| 650 | 7 | |a Tight junction |2 Elsevier | |
| 650 | 7 | |a Intestinal barrier dysfunction |2 Elsevier | |
| 650 | 7 | |a NLRP3 inflammasome |2 Elsevier | |
| 650 | 7 | |a Astragaloside IV |2 Elsevier | |
| 650 | 7 | |a RhoA |2 Elsevier | |
| 700 | 1 | |a Yang, Tao |4 oth | |
| 700 | 1 | |a Wang, Zhifen |4 oth | |
| 700 | 1 | |a Li, Man |4 oth | |
| 700 | 1 | |a Ding, Ling |4 oth | |
| 700 | 1 | |a Hu, Xiaotong |4 oth | |
| 700 | 1 | |a Geng, Licheng |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Laupland, Kevin B. ELSEVIER |t International immunopharmacology |d 2022 |g Amsterdam [u.a.] |w (DE-627)ELV00785823X |
| 773 | 1 | 8 | |g volume:78 |g year:2020 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.intimp.2019.106066 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 44.75 |j Infektionskrankheiten |j parasitäre Krankheiten |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 78 |j 2020 |h 0 | ||
| author_variant |
s x sx |
|---|---|
| matchkey_str |
xieshuhuayangtaowangzhifenlimandinglingh:2020----:srglsdiatnaespiidcdnetnlaredsucinisprsig |
| hierarchy_sort_str |
2020 |
| bklnumber |
44.75 |
| publishDate |
2020 |
| allfields |
10.1016/j.intimp.2019.106066 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001992.pica (DE-627)ELV048941867 (ELSEVIER)S1567-5769(19)32274-X DE-627 ger DE-627 rakwb eng 610 VZ 44.75 bkl Xie, Shuhua verfasserin aut Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • AS-Ⅳ alleviated abnormal permeability and TJ expression of gut induced by sepsis. • AS-Ⅳ inhibited RhoA/NLRP3 inflammasome signaling activated by sepsis. • AS-Ⅳ attenuated gut barrier impairment by suppressing RhoA/NLRP3 inflammasome. Sepsis Elsevier Tight junction Elsevier Intestinal barrier dysfunction Elsevier NLRP3 inflammasome Elsevier Astragaloside IV Elsevier RhoA Elsevier Yang, Tao oth Wang, Zhifen oth Li, Man oth Ding, Ling oth Hu, Xiaotong oth Geng, Licheng oth Enthalten in Elsevier Science Laupland, Kevin B. ELSEVIER International immunopharmacology 2022 Amsterdam [u.a.] (DE-627)ELV00785823X volume:78 year:2020 pages:0 https://doi.org/10.1016/j.intimp.2019.106066 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 78 2020 0 |
| spelling |
10.1016/j.intimp.2019.106066 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001992.pica (DE-627)ELV048941867 (ELSEVIER)S1567-5769(19)32274-X DE-627 ger DE-627 rakwb eng 610 VZ 44.75 bkl Xie, Shuhua verfasserin aut Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • AS-Ⅳ alleviated abnormal permeability and TJ expression of gut induced by sepsis. • AS-Ⅳ inhibited RhoA/NLRP3 inflammasome signaling activated by sepsis. • AS-Ⅳ attenuated gut barrier impairment by suppressing RhoA/NLRP3 inflammasome. Sepsis Elsevier Tight junction Elsevier Intestinal barrier dysfunction Elsevier NLRP3 inflammasome Elsevier Astragaloside IV Elsevier RhoA Elsevier Yang, Tao oth Wang, Zhifen oth Li, Man oth Ding, Ling oth Hu, Xiaotong oth Geng, Licheng oth Enthalten in Elsevier Science Laupland, Kevin B. ELSEVIER International immunopharmacology 2022 Amsterdam [u.a.] (DE-627)ELV00785823X volume:78 year:2020 pages:0 https://doi.org/10.1016/j.intimp.2019.106066 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 78 2020 0 |
| allfields_unstemmed |
10.1016/j.intimp.2019.106066 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001992.pica (DE-627)ELV048941867 (ELSEVIER)S1567-5769(19)32274-X DE-627 ger DE-627 rakwb eng 610 VZ 44.75 bkl Xie, Shuhua verfasserin aut Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • AS-Ⅳ alleviated abnormal permeability and TJ expression of gut induced by sepsis. • AS-Ⅳ inhibited RhoA/NLRP3 inflammasome signaling activated by sepsis. • AS-Ⅳ attenuated gut barrier impairment by suppressing RhoA/NLRP3 inflammasome. Sepsis Elsevier Tight junction Elsevier Intestinal barrier dysfunction Elsevier NLRP3 inflammasome Elsevier Astragaloside IV Elsevier RhoA Elsevier Yang, Tao oth Wang, Zhifen oth Li, Man oth Ding, Ling oth Hu, Xiaotong oth Geng, Licheng oth Enthalten in Elsevier Science Laupland, Kevin B. ELSEVIER International immunopharmacology 2022 Amsterdam [u.a.] (DE-627)ELV00785823X volume:78 year:2020 pages:0 https://doi.org/10.1016/j.intimp.2019.106066 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 78 2020 0 |
| allfieldsGer |
10.1016/j.intimp.2019.106066 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001992.pica (DE-627)ELV048941867 (ELSEVIER)S1567-5769(19)32274-X DE-627 ger DE-627 rakwb eng 610 VZ 44.75 bkl Xie, Shuhua verfasserin aut Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • AS-Ⅳ alleviated abnormal permeability and TJ expression of gut induced by sepsis. • AS-Ⅳ inhibited RhoA/NLRP3 inflammasome signaling activated by sepsis. • AS-Ⅳ attenuated gut barrier impairment by suppressing RhoA/NLRP3 inflammasome. Sepsis Elsevier Tight junction Elsevier Intestinal barrier dysfunction Elsevier NLRP3 inflammasome Elsevier Astragaloside IV Elsevier RhoA Elsevier Yang, Tao oth Wang, Zhifen oth Li, Man oth Ding, Ling oth Hu, Xiaotong oth Geng, Licheng oth Enthalten in Elsevier Science Laupland, Kevin B. ELSEVIER International immunopharmacology 2022 Amsterdam [u.a.] (DE-627)ELV00785823X volume:78 year:2020 pages:0 https://doi.org/10.1016/j.intimp.2019.106066 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 78 2020 0 |
| allfieldsSound |
10.1016/j.intimp.2019.106066 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001992.pica (DE-627)ELV048941867 (ELSEVIER)S1567-5769(19)32274-X DE-627 ger DE-627 rakwb eng 610 VZ 44.75 bkl Xie, Shuhua verfasserin aut Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • AS-Ⅳ alleviated abnormal permeability and TJ expression of gut induced by sepsis. • AS-Ⅳ inhibited RhoA/NLRP3 inflammasome signaling activated by sepsis. • AS-Ⅳ attenuated gut barrier impairment by suppressing RhoA/NLRP3 inflammasome. Sepsis Elsevier Tight junction Elsevier Intestinal barrier dysfunction Elsevier NLRP3 inflammasome Elsevier Astragaloside IV Elsevier RhoA Elsevier Yang, Tao oth Wang, Zhifen oth Li, Man oth Ding, Ling oth Hu, Xiaotong oth Geng, Licheng oth Enthalten in Elsevier Science Laupland, Kevin B. ELSEVIER International immunopharmacology 2022 Amsterdam [u.a.] (DE-627)ELV00785823X volume:78 year:2020 pages:0 https://doi.org/10.1016/j.intimp.2019.106066 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 78 2020 0 |
| language |
English |
| source |
Enthalten in International immunopharmacology Amsterdam [u.a.] volume:78 year:2020 pages:0 |
| sourceStr |
Enthalten in International immunopharmacology Amsterdam [u.a.] volume:78 year:2020 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Infektionskrankheiten parasitäre Krankheiten |
| institution |
findex.gbv.de |
| topic_facet |
Sepsis Tight junction Intestinal barrier dysfunction NLRP3 inflammasome Astragaloside IV RhoA |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
International immunopharmacology |
| authorswithroles_txt_mv |
Xie, Shuhua @@aut@@ Yang, Tao @@oth@@ Wang, Zhifen @@oth@@ Li, Man @@oth@@ Ding, Ling @@oth@@ Hu, Xiaotong @@oth@@ Geng, Licheng @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV00785823X |
| dewey-sort |
3610 |
| id |
ELV048941867 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV048941867</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624151147.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200108s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.intimp.2019.106066</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001992.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV048941867</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1567-5769(19)32274-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.75</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Xie, Shuhua</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• AS-Ⅳ alleviated abnormal permeability and TJ expression of gut induced by sepsis. • AS-Ⅳ inhibited RhoA/NLRP3 inflammasome signaling activated by sepsis. • AS-Ⅳ attenuated gut barrier impairment by suppressing RhoA/NLRP3 inflammasome.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sepsis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tight junction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Intestinal barrier dysfunction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NLRP3 inflammasome</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Astragaloside IV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RhoA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Tao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Zhifen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Man</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ding, Ling</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hu, Xiaotong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Geng, Licheng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Laupland, Kevin B. ELSEVIER</subfield><subfield code="t">International immunopharmacology</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00785823X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:78</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.intimp.2019.106066</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.75</subfield><subfield code="j">Infektionskrankheiten</subfield><subfield code="j">parasitäre Krankheiten</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">78</subfield><subfield code="j">2020</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Xie, Shuhua |
| spellingShingle |
Xie, Shuhua ddc 610 bkl 44.75 Elsevier Sepsis Elsevier Tight junction Elsevier Intestinal barrier dysfunction Elsevier NLRP3 inflammasome Elsevier Astragaloside IV Elsevier RhoA Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling |
| authorStr |
Xie, Shuhua |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00785823X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.75 bkl Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling Sepsis Elsevier Tight junction Elsevier Intestinal barrier dysfunction Elsevier NLRP3 inflammasome Elsevier Astragaloside IV Elsevier RhoA Elsevier |
| topic |
ddc 610 bkl 44.75 Elsevier Sepsis Elsevier Tight junction Elsevier Intestinal barrier dysfunction Elsevier NLRP3 inflammasome Elsevier Astragaloside IV Elsevier RhoA |
| topic_unstemmed |
ddc 610 bkl 44.75 Elsevier Sepsis Elsevier Tight junction Elsevier Intestinal barrier dysfunction Elsevier NLRP3 inflammasome Elsevier Astragaloside IV Elsevier RhoA |
| topic_browse |
ddc 610 bkl 44.75 Elsevier Sepsis Elsevier Tight junction Elsevier Intestinal barrier dysfunction Elsevier NLRP3 inflammasome Elsevier Astragaloside IV Elsevier RhoA |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
t y ty z w zw m l ml l d ld x h xh l g lg |
| hierarchy_parent_title |
International immunopharmacology |
| hierarchy_parent_id |
ELV00785823X |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
International immunopharmacology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV00785823X |
| title |
Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling |
| ctrlnum |
(DE-627)ELV048941867 (ELSEVIER)S1567-5769(19)32274-X |
| title_full |
Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling |
| author_sort |
Xie, Shuhua |
| journal |
International immunopharmacology |
| journalStr |
International immunopharmacology |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Xie, Shuhua |
| container_volume |
78 |
| class |
610 VZ 44.75 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Xie, Shuhua |
| doi_str_mv |
10.1016/j.intimp.2019.106066 |
| dewey-full |
610 |
| title_sort |
astragaloside iv attenuates sepsis-induced intestinal barrier dysfunction via suppressing rhoa/nlrp3 inflammasome signaling |
| title_auth |
Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling |
| abstract |
• AS-Ⅳ alleviated abnormal permeability and TJ expression of gut induced by sepsis. • AS-Ⅳ inhibited RhoA/NLRP3 inflammasome signaling activated by sepsis. • AS-Ⅳ attenuated gut barrier impairment by suppressing RhoA/NLRP3 inflammasome. |
| abstractGer |
• AS-Ⅳ alleviated abnormal permeability and TJ expression of gut induced by sepsis. • AS-Ⅳ inhibited RhoA/NLRP3 inflammasome signaling activated by sepsis. • AS-Ⅳ attenuated gut barrier impairment by suppressing RhoA/NLRP3 inflammasome. |
| abstract_unstemmed |
• AS-Ⅳ alleviated abnormal permeability and TJ expression of gut induced by sepsis. • AS-Ⅳ inhibited RhoA/NLRP3 inflammasome signaling activated by sepsis. • AS-Ⅳ attenuated gut barrier impairment by suppressing RhoA/NLRP3 inflammasome. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling |
| url |
https://doi.org/10.1016/j.intimp.2019.106066 |
| remote_bool |
true |
| author2 |
Yang, Tao Wang, Zhifen Li, Man Ding, Ling Hu, Xiaotong Geng, Licheng |
| author2Str |
Yang, Tao Wang, Zhifen Li, Man Ding, Ling Hu, Xiaotong Geng, Licheng |
| ppnlink |
ELV00785823X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| doi_str |
10.1016/j.intimp.2019.106066 |
| up_date |
2024-07-06T20:12:16.418Z |
| _version_ |
1803861870687289344 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV048941867</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624151147.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200108s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.intimp.2019.106066</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001992.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV048941867</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1567-5769(19)32274-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.75</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Xie, Shuhua</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• AS-Ⅳ alleviated abnormal permeability and TJ expression of gut induced by sepsis. • AS-Ⅳ inhibited RhoA/NLRP3 inflammasome signaling activated by sepsis. • AS-Ⅳ attenuated gut barrier impairment by suppressing RhoA/NLRP3 inflammasome.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sepsis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tight junction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Intestinal barrier dysfunction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NLRP3 inflammasome</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Astragaloside IV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RhoA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Tao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Zhifen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Man</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ding, Ling</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hu, Xiaotong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Geng, Licheng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Laupland, Kevin B. ELSEVIER</subfield><subfield code="t">International immunopharmacology</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00785823X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:78</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.intimp.2019.106066</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.75</subfield><subfield code="j">Infektionskrankheiten</subfield><subfield code="j">parasitäre Krankheiten</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">78</subfield><subfield code="j">2020</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.399392 |